Amoxicillin + clavulanic acid

Essential medicine status

General description

Amoxicillin is an extended spectrum penicillin antibiotic. Clavulanic acid is a beta-lactamase inhibitor.

INN	Amoxicillin + clavulanic acid
ATC codes	J01CR02
Medicine type	Chemical agent
Antibiotic groups	A ACCESS
EML status history	First added in 1997 (TRS 882) for Bacterial infection of unspecified site Added in 2017 (TRS 1006) for Acute otitis media Added in 2017 (TRS 1006) for Infectious cystitis Added in 2017 (TRS 1006) for Chronic obstructive pulmonary disease with acute exacerbation Added in 2017 (TRS 1006) for Acute sinusitis Added in 2017 (TRS 1006) for Bacterial cellulitis, erysipelas or lymphangitis Added in 2017 (TRS 1006) for Osteomyelitis or osteitis Added in 2017 (TRS 1006) for Bacterial infection of joint Removed in 2017 (TRS 1006) for Bacterial infection of unspecified site Added in 2017 (TRS 1006) for Neutropaenia Added in 2017 (TRS 1006) for Peritoneal abscess Added in 2017 (TRS 1006) for Peritonitis Added in 2017 (TRS 1006) for Bacterial pneumonia Added in 2017 (TRS 1006) for Other specified pneumonia Added in 2019 (TRS 1021) for Other specified prophylactic measures Added in 2019 (TRS 1021) for Multi-drug resistant Mycobacterium tuberculosis
Wikipedia	Amoxicillin + clavulanic acid
DrugBank	Amoxicillin, Clavulanic acid (Clavulanate)

Recommendations

Section Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

First choice

Chronic obstructive pulmonary disease with acute exacerbation

Infectious cystitis

Acute sinusitis

Bacterial cellulitis, erysipelas or lymphangitis

Neutropaenia (low-risk)

Peritoneal abscess (mild-moderate)

Peritonitis (mild-moderate)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Other specified pneumonia (Hospital-acquired pneumonia)

Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

Acute otitis media

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Bacterial pneumonia (Community-acquired pneumonia - severe)

Other specified prophylactic measures

Other indications

Bacterial infection of unspecified site

Section Antituberculosis medicines

- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

Multi-drug resistant Mycobacterium tuberculosis